ReviewCancer cell international2026
The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- GCAS: An Integrated R Package and Shiny App for Comprehensive Cancer Data Analysis.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need to elucidate its molecular mechanisms to improve treatment and prognosis. Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is aberrantly expressed in lung cancer and is closely associated with malignant progression. As a member of the m6A-modified RNA-binding proteins, IGF2BP3 recognizes and binds to m6A-modified RNAs, thereby regulating RNA stability and translation, ultimately influencing cell proliferation, tumorigenesis, and patient outcomes. This review aims to comprehensively explore the molecular mechanisms by which IGF2BP3 contributes to lung cancer development and progression, and to discuss its potential applications in diagnosis, prognostic assessment, and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.